Form 4: Director Jessica Grossman Receives DARE Stock Options

Director Jessica D. Grossman was granted 10,000 stock options in Dare Bioscience, Inc. as part of a standard equity compensation.

Summary

• Director Jessica D. Grossman acquired 10,000 stock options in Dare Bioscience, Inc. (DARE).
• The options have an exercise price of $2.03 per share.
• The grant date is June 11, 2026, with an expiration date of June 11, 2036.
• The options vest in full on the earlier of the first anniversary of the grant date or the date of the issuer's first annual meeting of stockholders following the grant.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• The value of the options is dependent on the future market performance of DARE common stock exceeding the $2.03 exercise price.

Future Outlook

The options vest in full on the earlier of the first anniversary of the grant date or immediately prior to the issuer's first annual meeting of stockholders occurring after the grant date, subject to continued service.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice in the biotechnology sector to ensure board members are incentivized to oversee long-term strategic growth.

Comparison to Industry Standards

• The grant of stock options to directors is consistent with standard compensation packages for small-cap biotechnology companies.
• The vesting schedule tied to annual meetings is a common practice to ensure director retention through the next governance cycle.

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of options on the earlier of June 11, 2027, or the next annual meeting of stockholders.

Key Dates

Keywords

Dare Bioscience, DARE, Form 4, Insider Trading, Stock Options, Director Compensation